293 related articles for article (PubMed ID: 9616206)
41. Cathepsin S is not crucial to TSHR processing and presentation in a murine model of Graves' disease.
Kala M; Chen CR; McLachlan SM; Rapoport B; Aliesky H; Chapman HA
Immunology; 2005 Dec; 116(4):532-40. PubMed ID: 16313367
[TBL] [Abstract][Full Text] [Related]
42. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus.
Nakagawa T; Roth W; Wong P; Nelson A; Farr A; Deussing J; Villadangos JA; Ploegh H; Peters C; Rudensky AY
Science; 1998 Apr; 280(5362):450-3. PubMed ID: 9545226
[TBL] [Abstract][Full Text] [Related]
43. Identification of putative cathepsin S in mangrove red snapper Lutjanus argentimaculatus and its role in antigen presentation.
Zhou J; Li L; Cai ZH
Dev Comp Immunol; 2012 May; 37(1):28-38. PubMed ID: 22210546
[TBL] [Abstract][Full Text] [Related]
44. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages.
Beers C; Honey K; Fink S; Forbush K; Rudensky A
J Exp Med; 2003 Jan; 197(2):169-79. PubMed ID: 12538657
[TBL] [Abstract][Full Text] [Related]
45. Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation.
Medd PG; Chain BM
Semin Cell Dev Biol; 2000 Jun; 11(3):203-10. PubMed ID: 10906277
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.
Mihelic M; Dobersek A; Guncar G; Turk D
J Biol Chem; 2008 May; 283(21):14453-60. PubMed ID: 18362148
[TBL] [Abstract][Full Text] [Related]
47. Glutathione depletion reveals impairment of antigen processing and inhibition of cathepsin activity by nitric oxide in antigen-presenting cells.
Lemaire G; Guittet O; Vesin MF; Lepoivre M; Cottet MH
Mol Immunol; 2009 Mar; 46(6):1100-8. PubMed ID: 19095306
[TBL] [Abstract][Full Text] [Related]
48. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
49. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.
Tolosa E; Li W; Yasuda Y; Wienhold W; Denzin LK; Lautwein A; Driessen C; Schnorrer P; Weber E; Stevanovic S; Kurek R; Melms A; Bromme D
J Clin Invest; 2003 Aug; 112(4):517-26. PubMed ID: 12925692
[TBL] [Abstract][Full Text] [Related]
50. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
51. Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM.
Villadangos JA; Driessen C; Shi GP; Chapman HA; Ploegh HL
EMBO J; 2000 Mar; 19(5):882-91. PubMed ID: 10698930
[TBL] [Abstract][Full Text] [Related]
52. Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.
Meyer zu Hörste G; Heidenreich H; Mausberg AK; Lehmann HC; ten Asbroek AL; Saavedra JT; Baas F; Hartung HP; Wiendl H; Kieseier BC
Neurobiol Dis; 2010 Feb; 37(2):483-90. PubMed ID: 19914379
[TBL] [Abstract][Full Text] [Related]
53. Expression of cathepsins B, L, S, and D by gastric epithelial cells implicates them as antigen presenting cells in local immune responses.
Barrera C; Ye G; Espejo R; Gunasena S; Almanza R; Leary J; Crowe S; Ernst P; Reyes VE
Hum Immunol; 2001 Oct; 62(10):1081-91. PubMed ID: 11600214
[TBL] [Abstract][Full Text] [Related]
54. Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone.
Manoury B; Mazzeo D; Li DN; Billson J; Loak K; Benaroch P; Watts C
Immunity; 2003 Apr; 18(4):489-98. PubMed ID: 12705852
[TBL] [Abstract][Full Text] [Related]
55. Difference in antigen presentation pathways between cortical and medullary thymic epithelial cells.
Kasai M; Hirokawa K; Kajino K; Ogasawara K; Tatsumi M; Hermel E; Monaco JJ; Mizuochi T
Eur J Immunol; 1996 Sep; 26(9):2101-7. PubMed ID: 8814253
[TBL] [Abstract][Full Text] [Related]
56. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
57. Mutation of the invariant chain transmembrane region inhibits II degradation, prolongs association with MHC class II, and selectively disrupts antigen presentation.
Frauwirth K; Shastri N
Cell Immunol; 2001 May; 209(2):97-108. PubMed ID: 11446742
[TBL] [Abstract][Full Text] [Related]
58. The p41 isoform of invariant chain is a chaperone for cathepsin L.
Lennon-Duménil AM; Roberts RA; Valentijn K; Driessen C; Overkleeft HS; Erickson A; Peters PJ; Bikoff E; Ploegh HL; Wolf Bryant P
EMBO J; 2001 Aug; 20(15):4055-64. PubMed ID: 11483509
[TBL] [Abstract][Full Text] [Related]
59. Proteases, processing, and thymic selection.
Cresswell P
Science; 1998 Apr; 280(5362):394-5. PubMed ID: 9575085
[No Abstract] [Full Text] [Related]
60. Immune complex-mediated antigen presentation induces tumor immunity.
Rafiq K; Bergtold A; Clynes R
J Clin Invest; 2002 Jul; 110(1):71-9. PubMed ID: 12093890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
